Extraskeletal Mesenchymal Chondrosarcoma, a Rare Entity with Unusual Metastases: A Case Report by Ali, Afaque et al.
J Cancer Allied Spec 2021;7(2):05
Journal Of Cancer & Allied Specialties 1
Case Report
Extraskeletal Mesenchymal Chondrosarcoma, a Rare Entity with Unusual 
Metastases: A Case Report
Afaque Ali, Sara Rehman, Kashif Siddique
Department of Radiology, Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, 
Pakistan
Received: 18 June 2021/Accepted: 09 July 2021
Abstract
Introduction: Extraskeletal mesenchymal chondrosarcoma (ESMC) is rare, 
aggressive, and high grade malignant tumors originating from soft tissues. 
It carries a poor prognosis with a tendency for local recurrence and distant 
metastasis, necessitating long-term follow-up. The most common sites for 
metastasis are the lungs, bones, and lymph nodes. Meanwhile, pancreatic 
metastases are extremely rare. Case Description: A  35-year-old female 
presented with a history of wide local excision for the left upper limb mass; 
histopathology showed ESMC. She was on surveillance with a computed 
tomography scan of the thorax and magnetic resonance imaging of the 
left upper limb at 3-months intervals until she developed vertebral and 
pancreatic lesions after 6 months post-surgery. No pulmonary metastases 
were noted. Considering the unusual site for metastasis and to exclude 
the possibility of any second malignancy, bone biopsy, and endoscopic 
ultrasound-guided fine-needle aspiration was performed that confirmed 
metastases. Later she developed osseous metastases in the pelvis and 
femora. Practical Implication: Pancreatic metastasis from ESMC is 
extremely rare. In case of new visceral or osseous lesions in a patient with a 
past medical history of ESMC, the possibility of metastatic disease should 
be considered. A biopsy can be performed to confirm the diagnosis.
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Introduction
Mesenchymal chondrosarcoma (MC) is a rare 
aggressive variant of chondrosarcoma, accounting 
for <10% of chondrosarcomas.[1,2] In contrast to 
conventional chondrosarcoma, only 1% of tumors 
are extraskeletal; MC has an extraskeletal location 
in 30–40% of cases.[3] Extraskeletal MC (ESMC) 
represent about 1% of all chondrosarcomas. Based 
on their location two subtypes of ESMC have 
been described: tumors occurring in muscle and 
soft tissues and those associated with the central 
nervous system.[1,2]
ESMC differ from conventional chondrosarcoma 
in several aspects. Conventional chondrosarcomas 
show a male predilection and typically arise in the 
pelvis and femur. Whereas EMCs have a slight 
female preponderance and shows bimodal peak 
age incidences corresponding with predominant 
Figure 1: Computed tomography scan sagittal images 
(a) soft-tissue window and (b) bone window show 
destructive lesion in T12 vertebral body with Grade 
3 compression fracture and extra osseous soft-tissue 
component extending into the spinal canal (red arrows)
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sites of origin. Central nervous system involvement 
occurs in patients aged 20–30  years and soft 
tissue involvement occurs in 40 years and older. 
Compared to chondrosarcoma, MC are quite 
aggressive, and have 5 and 10-year survival rates 
of 54.6% and 27.3%, respectively.[3,4]
ESMC commonly involves the orbit, meninges, 
and lower limbs. Upper limb involvement is rare.[3] 
Visceral involvement is also uncommon with few 
cases reported involving the kidney, spleen, 
pancreas and uterus.[5] Tumor size ranges from 5 
to 12  cm and are often well-  circumscribed and 
covered with a thin fibrous capsule.[2]
ESMC carries a dismal prognosis because of rapid 
growth, and the tendency for local recurrence and 
distant metastasis. Therefore, these patients require 
long-term follow-up.[6]
We report the case of a 35-years old female with 
a diagnosis of ESMC involving left upper limb 
who later developed osseous and pancreatic 
metastases. Our hospital Institutional Review Board 
granted a waiver of informed consent to publish 
this case report.
Case Description
A 35-year-old female with a medical history of 
progressively increasing painless left arm swelling 
for 1 year, underwent excision biopsy in an outside 
hospital facility. Histopathology revealed that ESMC, 
13.6 cm in size, was within 1 mm of the resection 
margin. Magnetic resonance imaging (MRI) left 
upper limb was performed that showed satisfactory 
post-surgical changes with no residual disease. 
Computed tomography (CT) scan through thorax 
was negative for pulmonary metastasis. Bone scan 
was also negative for distant osteoblastic metastasis. 
The case was discussed in Multidisciplinary Team 
(MDT), which recommended wide local excision 
of the scar. However, patient refused surgery and 
opted for surveillance.
Follow-up with CT thorax and MRI left upper limb 
was continued at three-month interval; there was no 
evidence of local disease recurrence or pulmonary 
metastasis. However, CT thorax at 6 months from 
presentation showed interval development of 
destructive lesion in T12 vertebral body with 
Grade  3 compression fracture and associated 
soft tissue component extending into spinal canal 
[Figure 1]. The patient was called to the emergency 
department, and a detailed medical history and 
physical examination were performed. She had a 
history of low back pain radiating to both legs for 
2 months. However, there was no motor or sensory 
loss or sphincter dysfunction.
Further evaluation was done with MRI of the 
whole spine with contrast to exclude myelopathy. 
MRI redemonstrated Grade  3 pathological 
compression fracture of T12 vertebral body with 
suspicious marrow infiltration and extraosseous 
soft-tissue extending posteriorly within the spinal 
canal deep to the posterior longitudinal ligament 
causing effacement of the anterior thecal sac and 
compression of the conus medullaris. No edema 
seen within the conus medullaris [Figure 2]. The 
rest of the vertebral bodies were unremarkable 
with no evidence of metastasis. In addition to this, 
a note was made of a rim enhancing lesion in the 
body of the pancreas.
Furthermore, CT abdomen and pelvis with contrast 
was performed that showed a hypodense lesion 
measuring 13 mm × 9 mm in the body of pancreas on 
ba
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the background of normal pancreatic parenchyma 
without any surrounding fat arborization [Figure 3]. 
While the follow-up MRI of the left limb showed 
stable post-surgical changes with no evidence 
of local disease recurrence. These findings 
were discussed in MDT to decide the further 
management plan. As patient did not develop 
local recurrence and pulmonary metastasis; CT 
guided biopsy was recommended for T12 vertebral 
body lesion for histopathological confirmation of 
metastasis and exclude the possibility of second 
primary bone tumor. In addition, an endoscopic 
ultrasound (EUS) guided fine-needle aspiration 
(FNA) for pancreatic lesion was planned. A  CT 
guided bone biopsy was performed [Figure 4] and 
histopathology confirmed metastatic MC.
Diagnosis and Management
The patient was discussed in neurology MDT 
and was planned for spinal decompression and 
stabilization surgery. She underwent T10-L3 
pedicle screw fixation, T12 Laminectomy and 
tumor debulking the by neurosurgery team. 
Histopathology of post-operative specimen 
again confirmed metastatic MC. After the patient 
Figure 2: Sagittal magnetic resonance images through thoracolumbar spine show Grade 3 pathological compression 
fracture of T12 vertebral body with altered marrow signals; intermediate on T2-weighted imaging (WI) (a), hyperintense 
on Short Tau Inversion recovery sequence (b) and hypointense on T1WI (c). Post-contrast T1WI (d) shows enhancing 
soft tissue component extending posteriorly within spinal canal deep to posterior longitudinal ligament causing 
effacement of the anterior thecal sac and compression of the conus medullaris (red arrow). Enhancing soft-tissue 
component is noted anteriorly as well beneath anterior longitudinal ligament (blue arrow)
dcba
Figure 3: Contrast-enhanced computed tomography through abdomen axial section (a) shows a hypodense lesion 
in the body of the pancreas. This lesion was showing a heterogeneous signal on T2WI (b) and TIWI (c) and peripheral 
rim enhancement on post-contrast TIWI (d) in previously performed magnetic resonance imaging spine (shown by 
the blue arrow)
dcba
Figure  6:  Axial contrast-enhanced computed 
tomography through abdomen shows the development 
of calcifications in metastatic pancreatic lesion
Figure 5: Endoscopic ultrasound image shows a 24 mm 
rounded solid, hypoechoic lesion in the body of the 
pancreas. Background pancreas tissue appeared normal. 
Using a 22 gauge needle, four passes were made and 
tissue obtained for cytologic evaluation.
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had recovered from surgery, EUS guided FNA 
was performed for pancreatic lesion [Figure  5], 
cytopathology showed chondroid neoplasm, 
compatible with the patient’s known history of MC.
She was started on Vincristine, Doxorubicin and 
Cyclophosphamide/Ifosfamide and Etoposide 
(VDC/IE) chemotherapy as per MDT discussion. 
However, while she was admitted for the fourth 
cycle of chemotherapy, she developed a worsening 
backache; without any apparent neurological 
deficit. MRI whole spine was performed that 
showed interval increase in extraosseous soft-
tissue component and terminal spinal cord 
compression. Emergency radiotherapy was 
given to the thoracolumbar spine with a total 
dose of 2000c Gray in five fractions. Her pain 
was improved, and she was discharged on oral 
analgesics.
Follow-up CT showed marginal interval decrease 
in size of the pancreatic lesion, measuring 17 mm 
× 25  mm against the previous measurement of 
22 mm × 27 mm with the development of internal 
calcifications [Figure  6]. She underwent regular 
follow-up with CT chest abdomen and pelvis at 
intervals of 3  months. CT done after 6 months 
showed stable pancreatic lesion and changes 
of spinal fixation surgery; however, there was a 
development of lytic lesions in bilateral femora 
and left acetabulum [Figure 7]. Further evaluation 
with MRI was performed that confirmed abnormal 
marrow signals consistent with metastasis [Figure 8]. 
The patient was evaluated by the orthopedic team. 
She had complaint of pain in both legs, which was 
more on the left side. She received prophylactic 
radiotherapy to the left femur (2000 cGray in 5 
fractions), which resulted in pain improvement. Her 
examination and clinical review were unremarkable 
until the last follow-up. Additional follow-up 
imaging has not yet been done. 
Figure  4: (a and b) show images of computed 
tomography-guided bone biopsy performed for T12 
vertebral body lesion. A 10-G MADISON bone biopsy 
system was parked over the right pedicle of the T12 
vertebra. Two cores were obtained from the T12 
vertebral body using the transpedicle approach
ba
Figure 7: Computed tomography pelvis bone window 
coronal images (a and b) show lucent lesion with internal 
chondroid matrix involving the left femoral neck and 
greater trochanter (red arrow), right femur close to 
lesser trochanter (blue arrow), and left acetabulum 
(green arrow)
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Discussion
ESMC are rare high-grade malignant tumors 
originating from soft tissues. A plain radiograph is 
usually obtained as an initial investigation that often 
shows a soft tissue mass with areas of chondroid 
matrix appearing as arc-shaped or stippled 
calcification. However, there are limitations to 
this approach due to the overlapping of adjacent 
structures and poor resolution.[3,4] On CT, ESMC 
appears as lobulated well-circumscribed soft-
tissue mass with areas of granular, ring and arc or 
irregular coarse calcifications with peripheral post-
contrast enhancement.[2,3] On MRI, the soft-tissue 
component appears as isointense or hypointense 
on T1 weighted imaging (WI) and heterogenous on 
T2WI. Furthermore, mineralized and non-calcified 
areas appear as hypointense and hyperintense 
areas respectively. This is often termed as the black 
pepper sign. Post-contrast images show diffuse 
heterogeneous or nodular enhancement.[4]
Diagnosis is based on tumor morphology and 
various immunohistochemical stains. Histologically, 
the tumor has a bimorphic morphology composed 
of undifferentiated round blue cells and hyaline 
carti lage.[4,5] EMCS can be challenging to 
diagnose with certainity in cases of small biopsy 
specimens that show only one of the two tissue 
elements especially in cases without cartilaginous 
components. The differential diagnosis for EMSC 
includes hemangiopericytoma, synovial sarcoma, 
malignant solitary fibrous tumor, Ewing Sarcoma, 
and other round blue cell tumors and other variants 
of chondrosarcoma.[2,3]
Because of the rarity of the tumor, the potential 
benefits of radiation and chemotherapy are unclear. 
Wide local excision of tumor is considered the 
main stay of treatment. According to the National 
Comprehensive Cancer Network guidelines 
recommendation, MC can be treated with VDC 
alternating with IE. This is a treatment regimen used 
typically in cases of Ewing’s sarcoma.[4]
Metastasis from ESMC has been reported to occur 
in <20% of patients occurring over a period of 
10 months–8 years.[6] Pulmonary, bone, and lymph 
node metastasis are usually seen at the time of 
diagnosis. The most common site for metastasis are 
the lungs, and it carries a poor prognosis.[1] The size 
of metastatic deposits ranges from 2 cm to 12 cm.[5]
Osseous metastatic lesions appear as lytic lesions on 
plain radiographs. CT scans often demonstrate soft 
tissue density mass with calcification foci.[7] These 
findings were also noted in our patient. Osseous 
metastatic lesions show increased uptake on bone 
scan and positron emission tomography/CT.[7,8] 
Figure  8: Magnetic resonance imaging pelvis coronal sections show STIR hyperintense (a), T1WI hypointense 
(b), enhancing lesions on post-contrast T1WI (c) in the right proximal femur near lesser trochanter (blue arrow), left 
acetabulum (green arrow), and left femoral neck and greater trochanter (red arrow)
cba
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Although these imaging features suggest metastatic 
disease, bone biopsy helps in histopathological 
confirmation of diagnosis.[7,9] Osseous metastatic 
lesions treated with radiotherapy often show 
calcification and well-defined sclerotic margin.[7]
Pancreatic metastases from ESMC are extremely 
rare. Only 8 cases have been previously reported 
in the literature with latency periods ranging from 
3 years to 21 year and previously, just one case has 
been reported with synchronous presentation.[5,8,10,11] 
Pancreatic metastases are usually accompanied by 
concurrent metastasis to other organs like lungs, 
lymph nodes, bones and kidneys. Primary ESMC 
involving the pancreas is also a rare entity with only 
two previously reported cases.[5] Pancreatic metastatic 
lesions account for <7% of all pancreatic masses, with 
the most common primary being kidney and lung.[11] 
Patients can be asymptomatic and diagnosed on 
surveillance imaging. When symptomatic they usually 
present with abdominal pain and jaundice.[5] On CT, 
metastatic pancreatic lesions appear as a hypodense 
tumor with granular irregular calcifications. On MRI 
tumor is hyperintense on T2WI with internal low signal 
areas corresponding to calcifications. Our patient had 
an incidental diagnosis of pancreatic lesion, which 
demonstrated similar imaging features as detailed 
above. Calcifications were noted after treatment with 
an interval decrease in the size of tumor. The presence 
of a pancreatic lesion in a patient with a history of 
malignancy should raise suspicion of metastasis. 
EUS-guided fine-needle aspiration cytology should 
be performed to confirm the diagnosis.[5]
This case report is one of few cases of ESMC with 
several unique features. Firstly, ESMC involving 
muscle and soft tissue most commonly arises 
from the lower limb. Upper limb involvement 
has an extremely rare occurrence. Second, lungs 
are the most common site for metastatic disease, 
which was not seen in our case; instead the 
patient developed pancreatic metastasis, which 
is exceedingly rare. Imaging finds its role in long-
term follow-up of these patients to detect the 
development of metastasis and local recurrence, 
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